Peripheral T-cell lymphoma · 2 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bortezomib and Panobinostat Variant #01 Partial | — | R 6 762 | 21d | — | — | ~8 | ~R 54 096 indirect | — |
Romidepsin monotherapy Variant #01 Partial | — | — | 28d | — | — | ~6 | — | 1 |
2 of 2 regimens shown